Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 10, 2014

L’Oréal Inks Deal with Evolva for Cosmetics Ingredient

  • Evolva Holding is collaborating with cosmetics firm L’Oréal to co-develop biosynthetic production routes for an undisclosed ingredient that the firms claim has broad applications in the cosmetics industry. The two companies are going to use Evolva’s fermentation technology platform to develop and optimize yeast strains for the sustainable production of the ingredient.

    This collaboration will end in late 2016 but comes with an option to expand the ingredient focus. L’Oréal will pay Evolva research fees for the duration of the project, plus Evolva could also receive milestone payments for reaching research objectives.

    Evolva claims its yeast and fermentation platform can produce valuable ingredients that normally industry would have a hard time accessing due to cost, sustainability, and other issues. Luc Aguilar, the global head of L’Oréal’s biotechnologies department, added in a statement that the firm believes this platform "could end in new cosmetic ingredients bringing a real breakthrough for our customers."



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »